Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000622386 | SCV000742071 | pathogenic | Inborn genetic diseases | 2016-12-16 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV002247241 | SCV002520041 | pathogenic | not provided | 2021-12-27 | criteria provided, single submitter | clinical testing | PP1, PM2, PM3, PS3, PVS1 |
Genome- |
RCV000002374 | SCV003931399 | pathogenic | Spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 2 | 2023-02-08 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000002374 | SCV000022532 | pathogenic | Spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 2 | 2004-03-01 | no assertion criteria provided | literature only | |
Prevention |
RCV004732525 | SCV005367268 | pathogenic | SETX-related disorder | 2024-05-27 | no assertion criteria provided | clinical testing | The SETX c.4087C>T variant is predicted to result in premature protein termination (p.Arg1363*). This variant was reported in multiple unrelated individuals with ataxia-ocular apraxia 2 (Moreira et al. 2004. PubMed ID: 14770181; Table S1, Capalbo et al. 2019. PubMed ID: 31589614; da Costa et al. 2022. PubMed ID: 35426160; Baviera-Muñoz et al. 2022. PubMed ID: 36530930). This variant is reported in 0.0004% of alleles in individuals in gnomAD; and has been consistently classified as pathogenic in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/2284/). Nonsense variants in SETX are expected to be pathogenic. This variant is interpreted as pathogenic. |